Abstract: Multiplex immunoassays utilize the differential affinities among the conjugation pairs between the capture ligands and target analytes are proposed. Window magnetic-assisted rapid aptamer selection (window-MARAS) methods for selecting aptamers with desirable affinity toward the target analytes and methods for generating reagents for multiplex immunoassays or multiplex detection in one assay by utilizing the selected aptamers as capture ligands in reagents are described and used to demonstrate the feasibility of multiplex immunoassays based on the differential affinity of conjugation pairs between the capture ligands and target analytes.
Abstract: Nucleic acid molecules such as shRNA clusters and artificial miRNA clusters are disclosed, Also disclosed are methods of use, compositions, cells, viral particles, and kits relating to the nucleic acid molecules disclosed herein. The disclosure provides, at least in part nucleic acid molecules such as shRNA clusters encoding shRNA-like molecules and artificial miRNA clusters encoding modified pri-miRNA-like molecules. The shRNA clusters and artificial miRNA clusters disclosed herein can be used, for example, to produce artificial RNA molecules, e.g., RNAi molecules. Cells, viral particles, compositions (e.g., pharmaceutical compositions), kits, and methods relating to the nucleic acid molecules, e.g., shRNA clusters and artificial miRNA clusters, are also disclosed. The nucleic acid molecules (e.g., shRNA clusters and artificial miRNA clusters), artificial RNA molecules (e.g., RNAi molecules), cells, viral particles, compositions (e.g.
Abstract: The present disclosure generally relates to nanoparticles comprising an endo-lysosomal escape agent, a nucleic acid, and a polymer. Other aspects include methods of making and using such nanoparticles.
Type:
Grant
Filed:
May 24, 2018
Date of Patent:
March 23, 2021
Assignee:
Pfizer Inc.
Inventors:
Allen Thomas Horhota, Young-Ho Song, Ujjwal Chaitanya Joshi, Nicholas Jon Boylan, Matthew John Simmons
Abstract: The present invention relates to nucleic acid molecules that simultaneously inhibit the expression of AR gene and mTOR gene, wherein the double-stranded siRNA and shRNA of the present invention were designed to simultaneously inhibit the expression of the AR gene and the mTOR gene which are associated with cancer. The double-stranded siRNA and shRNA of the present invention promote cancer cell death and synergistically enhance cancer cell death in combination with an anticancer agent, so that various types of cancer may be effectively prevented and treated.
Abstract: The present invention provides a small hairpin nucleic acid molecule that is capable of stimulating interferon production. The nucleic acid molecule of the present invention has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises a 5? triphosphate or a 5? diphosphate.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
March 16, 2021
Assignee:
Yale University
Inventors:
Anna Marie Pyle, Andrew Kohlway, Dahai Luo, David Rawling, Akiko Iwasaki
Abstract: The present invention generally relates to bacterial polypeptide display systems, libraries using these bacterial display systems, and methods of making and using these systems, including methods for improved display of polypeptides on the extracellular surface of bacteria using circularly permuted transmembrane bacterial polypeptides that have been modified to increase resistance to protease degradation and to enhance polypeptide display characteristics.
Type:
Grant
Filed:
March 28, 2016
Date of Patent:
March 16, 2021
Assignee:
CytomX Therapeutics, Inc.
Inventors:
Sherry Lynn La Porte, Stephen James Moore, James William West
Abstract: Disclosed are compositions and methods related to RNA interference (RNAi) and the use of RNAi active sequence for treating diseases and disorders. Particular disclosed are toxic RNAi active sequences such as siRNA and shRNA for killing cancer cells. The disclosed toxic RNAi active sequences typically include trinucleotide repeats and preferentially target the expression of multiple essential genes for cell survival and/or growth.
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for LDHA.
Type:
Grant
Filed:
October 25, 2018
Date of Patent:
February 16, 2021
Assignee:
Thermo Fisher Scientific Inc.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: This invention relates to an oligonucleotide comprising one or more abasic nucleoside monomers of formula V: These monomers are useful for modifying of oligonucleotides at one or more positions. This invention also relates to a method of inhibiting the expression of a target gene in a cell. The method comprises contacting the cell with an oligonucleotide having one or more of the above formula (V).
Type:
Grant
Filed:
April 22, 2011
Date of Patent:
February 9, 2021
Assignee:
ALNYLAM PHARMACEUTICALS, INC.
Inventors:
Muthiah Manoharan, Kallanthottathil G. Rajeev, Jeremy Lackey, Narayanannair K. Jayaprakash
Abstract: Compositions and methods for enhancing delivery of molecules, e.g. biological agents, into cells are described. The composition is a conjugate of the biological agent, preferably a nucleic acid analog having a substantially uncharged backbone, covalently linked to a peptide transporter moiety as described. Conjugation of the peptide transporter to a substantially uncharged nucleic acid analog, such as a morpholino oligomer, is also shown to enhance binding of the oligomer to its target sequence and enhance antisense activity.
Type:
Grant
Filed:
April 9, 2019
Date of Patent:
February 2, 2021
Assignee:
Sarepta Therapeutics, inc.
Inventors:
Patrick L. Iversen, Hong M. Moulton, Michelle H. Nelson, David A. Stein, Andrew D. Kroeker
Abstract: New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes.
Abstract: Antisense compounds for suppressing expression of ARTD3a are disclosed, as well as pharmaceutical compositions containing same and methods of producing and using same. The antisense compounds can be used to treat inflammatory disorders and conditions related to interferon-alpha production.
Type:
Grant
Filed:
July 14, 2017
Date of Patent:
December 29, 2020
Assignee:
The Board of Regents of the University of Oklahoma
Inventors:
Carol F. Webb, Julie Ward, Michelle Ratliff
Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.
Type:
Grant
Filed:
February 26, 2018
Date of Patent:
December 29, 2020
Assignee:
Isis Pharmaceuticals, Inc.
Inventors:
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
Type:
Grant
Filed:
October 12, 2018
Date of Patent:
November 17, 2020
Assignees:
Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
Inventors:
Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
Abstract: This invention covers oligonucleotide analogs that fold in part by having a segment of consecutive pyrimidine analogs form pyrimidine analog:pyrimidine analog pairs with another a segment of consecutive pyrimidine analogs segment, and where the segments pair by pyrimidine analog:pyrimidine analog “skinny” pairing. This pairing retains hydrogen bonding complementarity seen in standard DNA.
Abstract: This invention relates to processes that amplify oligonucleotide analogs that incorporate non-standard nucleobase analogs from an artificially expanded genetic information system. These pair in DNA duplexes via patterns of hydrogen bonds that differ from patterns that join the thymine-adenine and guanine-cytosine nucleobase pairs.
Type:
Grant
Filed:
December 11, 2018
Date of Patent:
November 10, 2020
Inventors:
Steven A Benner, Roberto Laos, Nicole A Leal, Zunyi Yang, Myong Jung Kim
Abstract: The invention relates to a method of identifying stereodefined phosphorothioate oligonucleotide variants with reduced toxicity by creating and screening libraries of stereodefined chiral phosphorothioate variants for compounds with reduced toxicity, either in vitro or in vivo.
Type:
Grant
Filed:
December 16, 2015
Date of Patent:
October 27, 2020
Assignee:
Roche Innovation Center Copenhagen A/S
Inventors:
Henrik Frydenlund Hansen, Troels Koch, Sabine Sewing, Nanna Albaek, Peter Hagedorn, Jacob Ravn, Christoph Rosenbohm, Annie Moisan, Marcel Gubler
Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 mRNA and protein in an animal. Such methods are useful to treat, prevent, ameliorate, or slow progression of neurodegenerative diseases in an individual in need thereof.